# OnCo record paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024" ;
  schema:name "Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial"@en ;
  schema:description "The antibody-drug conjugate trastuzumab deruxtecan shrank tumours in about a third of Japanese patients with HER2-positive bile duct or gallbladder cancer after chemotherapy, and in one in eight with low HER2, but a quarter developed lung inflammation and two died of it."@en ;
  schema:url <https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.23.02010>, <https://pubmed.ncbi.nlm.nih.gov/39102634/> ;
  schema:sameAs <https://doi.org/10.1200/jco.23.02010> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Ohba A, Morizane C, Kawamoto Y, et al." ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/ncc-japan/> ;
  onco:journals <https://onco.cc/journals/jco/> .